Zhejiang Shouxiangu Pharmaceutical Holding Co. Ltd. Class A

Zhejiang Shouxiangu Pharmaceutical Holding Co. Ltd. Class A

SSSE:603896
13.36
CNY
-0.09
(-0.67%)
-0.09EPS
2.94BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.86
2.21
2.22
2.3
2.27
2.78
2.99
3.45
4.01
4.27
4.01
3.56
3.17
3
Basic EPS, GAAP
0.4
0.51
0.46
0.59
0.55
0.58
0.68
0.82
1.05
1.43
1.3
0.88
0.09
-0.09
Free Cash Flow per Basic Share
- -
-0.24
-0.34
0.4
0.49
-0.33
0.64
1.04
0.71
0.82
-0.51
-1.47
-0.22
- -
Dividend per Share
0.25
0.35
0.19
0.14
0.12
0.16
0.18
0.27
0.25
0.31
0.47
0.42
0.29
0.03
Book Value per Share
2.2
2.35
2.7
3.21
4.79
5.42
6.27
6.89
8.17
9.66
10.76
11.56
11.4
11.63
Tangible Book Value per Share
2.17
2.33
2.25
2.64
4.36
5.02
5.84
6.48
7.75
9.27
9.22
9.78
9.61
9.89
Basic Weighted Avg Shares
136
136
136
137
163
184
183
184
191
194
196
198
202
197
Sales/Revenue/Turnover
253
302
302
315
370
511
547
636
767
829
784
705
640
591
Operating Margin (%)
22.84
21.23
20.99
24.12
23.17
19.44
20.85
24.56
26.07
32.25
28.87
19.82
19.35
17.44
Depreciation Expense
- -
21
35
39
37
39
41
43
54
64
76
81
93
- -
Net Income, GAAP
54
69
63
81
89
108
124
152
201
278
254
174
18
-18
Effective Tax Rate (%)
1.77
0.4
- -
- -
- -
2.21
0.88
1.29
0.37
0.16
0.17
0.03
82.26
126.83
Profit Margin (%)
21.36
22.96
20.75
25.72
24.02
21.05
22.66
23.85
26.18
33.51
32.44
24.74
2.84
-2.97
Working Capital
143
-29
-67
1
436
336
455
753
846
1,384
1,222
1,127
925
966
LT Debt
11
- -
- -
- -
- -
- -
- -
201
101
429
364
384
403
421
Total Equity
299
321
369
437
870
1,010
1,172
1,326
1,620
1,906
2,171
2,291
2,260
2,308
Return on Invested Capital (%)
18.72
16.72
- -
- -
- -
11.2
11.3
11.53
12.67
12.92
9.18
6.03
0.77
-0.88
Return on Capital (%)
21.06
18.2
- -
- -
- -
11.32
11.19
12.04
12.99
13.42
10.09
6.53
0.78
-0.85
Return on Common Equity (%)
24.69
22.34
18.18
20.11
13.6
11.46
11.36
12.14
13.63
15.76
12.48
7.82
0.8
-0.76

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
157
236
197
LT Borrowings
389
396
403
LT Finance Leases
19
17
19
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
198
198
198
Market Capitalization
3,685
2,567
2,938

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,415
1,403
1,367
Cash, Cash Equivalents & STI
1,058
1,036
995
Accounts Receivable, Net
74
57
60
Inventories
220
245
255
Total Current Liabilities
452
448
401
Payables & Accruals
- -
- -
- -
ST Debt
157
236
197
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
22.09%
11.58%
-1.35%
Free Cash Flow
-64.53%
-13.11%
-84.54%
Net Income, GAAP
3.9%
-11.75%
-89.58%
Sales/Revenue/Turnover
8.72%
0.8%
-9.21%
Total Cash Common Dividend
12.65%
7.48%
-28.32%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
221
132
119
220
705
2025
176
129
- -
210
640
2026
161
115
105
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.39
0.12
0.09
0.28
0.88
2025
0.29
0.04
- -
-0.29
0.09
2026
0.15
0.04
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.01
0.01
0.42
2025
- -
- -
- -
0.02
0.29
2026
- -
- -
- -
- -
- -

Company Description

CEO
Zhen Yu Li
Full Time Employees
1,119
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
No. 12, Huanglong Third Road Jinhua ZH China 321200
IPO Date
May 10, 2017
Business
Zhejiang Shouxiangu Pharmaceutical Co., Ltd. is a China-based enterprise specializing in the research, development, breeding, cultivation, processing, and sale of traditional Chinese medicinal materials. Founded in 1997 and headquartered in Jinhua, Zhejiang Province, the company operates mainly in the domestic market through wholesaling and direct sales channels. Its core product portfolio includes ganoderma lucidum spore powder (broken wall and granules), ganoderma lucidum extract products, dendrobium officinale and its granules, saffron extract, crocus sativus, Tiepi Fengdou granules, and fresh dendrobium officinale. The company is recognized as a national high-tech enterprise and holds industry leadership in developing and standardizing Lingzhi and Tiepishihu medicinal products. It has contributed to the creation of ISO international standards and local provincial standards for these traditional Chinese medicines, enhancing product quality and cultivation techniques industry-wide. In the recent 1-2 years, Zhejiang Shouxiangu Pharmaceutical has achieved significant regulatory milestones, including China registration for its ganoderma lucidum spore powder and filing certificates for related products such as broken ganoderma lucidum spore powder tablets through its wholly owned subsidiaries. These advances support its product expansion and market penetration efforts. The company maintains its strategic focus on innovation, quality control, and standardization in traditional Chinese medicine, reinforcing its position as a market leader in herbal pharmaceutical manufacturing in China. Zhejiang Shouxiangu serves health-conscious consumers and pharmaceutical distributors, with its product lines encompassing herbal health supplements and medicinal extracts primarily used for wellness and therapeutic purposes. It leverages its extensive cultivation expertise and proprietary processing technologies to maintain product efficacy and safety. The company employs over 1,100 staff and continues to expand its influence in the healthcare and alternative medicine sectors within China, underscored by a series of product registrations and enhancements in operational capabilities. This profile highlights Zhejiang Shouxiangu Pharmaceutical Co., Ltd.’s commitment to traditional Chinese medicine through a comprehensive range of herbal products, recent major regulatory achievements that facilitate growth, and a strategic emphasis on research and development stemming from its establishment and longstanding presence in the Chinese pharmaceutical industry. The company remains a significant player in China's ganoderma lucidum and dendrobium officinale markets, with contributions to industry standards strengthening its competitive advantage and operational excellence. All information is accurate and reflects the latest available data as of late 2025.